Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

The Advanced Prostate Cancer Pipeline: A Continuum

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Drug development in advanced prostate cancer typically moves along a continuum, first targeting either castration-resistant (hormone-refractory) patients who have already taken the first-line chemotherapy docetaxel or the larger population of those who are chemotherapy-naïve after failing medical and surgical castration. Drugs that can reach into the hormone-sensitive prostate cancer population would reach even more patients. Below are selected drugs in late-stage development for advanced prostate cancer and their progress in the various indications.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS004921

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel